Itraclar SB Capsule contains Itraconazole 50 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of dermatophytosis, onychomycosis, candidiasis, and other systemic and superficial mycoses caused by susceptible fungal pathogens. Itraclar SB Capsule is particularly effective against infections caused by dermatophytes, yeasts, and certain molds. It is administered orally, with absorption enhanced when taken with food. The pharmacokinetic profile of itraconazole allows for effective tissue penetration, including skin, nails, and mucous membranes, ensuring targeted antifungal activity. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored during prolonged therapy. Itraclar SB Capsule should be used under medical supervision, with attention to potential drug interactions due to itraconazole’s inhibition of cytochrome P450 enzymes. It is contraindicated in patients with hypersensitivity to itraconazole or other azole antifungals.